Ken Griffin Amneal Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Amneal Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 600 shares of AMRX stock, worth $4,698. This represents 0.0% of its overall portfolio holdings.

Number of Shares

600

Previous 9,400 93.62%

Holding current value

$4,698

Previous $78,000 94.87%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$7.69 - $9.25 $681,910 - $820,243	88,675 Added 1.0%	8,980,968 $71.1 Million
Q3 2024 Nov 14, 2024	SELL	$6.42 - $8.83 $7.04 Million - $9.68 Million	-1,096,432 Reduced 10.98%	8,892,293 $74 Million
Q2 2024 Aug 14, 2024	BUY	$5.36 - $7.11 $26.4 Million - $35 Million	4,921,242 Added 97.11%	9,988,725 $63.4 Million
Q1 2024 May 15, 2024	SELL	$5.24 - $6.34 $7.49 Million - $9.06 Million	-1,429,607 Reduced 22.0%	5,067,483 $30.7 Million
Q4 2023 Feb 14, 2024	BUY	$3.36 - $6.21 $12.8 Million - $23.6 Million	3,808,360 Added 141.64%	6,497,090 $39.4 Million
Q3 2023 Nov 14, 2023	BUY	$2.76 - $4.59 $4.12 Million - $6.85 Million	1,493,222 Added 124.9%	2,688,730 $11.3 Million
Q2 2023 Aug 14, 2023	BUY	$1.33 - $3.1 $213,205 - $496,945	160,305 Added 15.49%	1,195,508 $3.71 Million
Q1 2023 May 15, 2023	BUY	$1.27 - $2.7 $438,720 - $932,712	345,449 Added 50.08%	1,035,203 $1.44 Million
Q4 2022 Feb 14, 2023	SELL	$1.96 - $2.61 $1.88 Million - $2.5 Million	-956,839 Reduced 58.11%	689,754 $1.37 Million
Q3 2022 Nov 14, 2022	BUY	$2.02 - $3.62 $429,660 - $769,984	212,703 Added 14.83%	1,646,593 $3.33 Million
Q2 2022 Aug 15, 2022	SELL	$3.01 - $4.46 $94,002 - $139,285	-31,230 Reduced 2.13%	1,433,890 $4.56 Million
Q1 2022 May 16, 2022	SELL	$3.9 - $4.89 $510,225 - $639,744	-130,827 Reduced 8.2%	1,465,120 $6.11 Million
Q4 2021 Feb 14, 2022	BUY	$3.95 - $5.85 $1.72 Million - $2.54 Million	435,040 Added 37.47%	1,595,947 $7.64 Million
Q3 2021 Nov 15, 2021	BUY	$4.31 - $5.64 $2.31 Million - $3.02 Million	534,969 Added 85.47%	1,160,907 $6.2 Million
Q2 2021 Aug 16, 2021	BUY	$5.12 - $6.82 $27,765 - $36,984	5,423 Added 0.87%	625,938 $3.2 Million
Q1 2021 May 17, 2021	SELL	$4.74 - $7.38 $4.07 Million - $6.34 Million	-859,409 Reduced 58.07%	620,515 $4.18 Million
Q4 2020 Feb 16, 2021	BUY	$3.95 - $5.42 $681,758 - $935,475	172,597 Added 13.2%	1,479,924 $6.76 Million
Q3 2020 Nov 16, 2020	BUY	$3.54 - $5.27 $2.54 Million - $3.78 Million	717,014 Added 121.46%	1,307,327 $5.07 Million
Q2 2020 Aug 14, 2020	BUY	$2.87 - $5.46 $685,175 - $1.3 Million	238,737 Added 67.9%	590,313 $2.81 Million
Q1 2020 May 15, 2020	SELL	$2.46 - $5.35 $215,825 - $469,376	-87,734 Reduced 19.97%	351,576 $1.22 Million
Q4 2019 Feb 14, 2020	SELL	$2.65 - $5.56 $559,004 - $1.17 Million	-210,945 Reduced 32.44%	439,310 $2.12 Million
Q3 2019 Nov 14, 2019	BUY	$2.29 - $7.1 $169,240 - $524,718	73,904 Added 12.82%	650,255 $1.89 Million
Q2 2019 Aug 14, 2019	SELL	$6.44 - $14.29 $182,142 - $404,164	-28,283 Reduced 4.68%	576,351 $4.13 Million
Q2 2018 Aug 10, 2018	BUY	$13.95 - $20.2 $8.43 Million - $12.2 Million	604,634 New	604,634 $0

Others Institutions Holding AMRX

# of Institutions

205

Shares Held

123M

Call Options Held

362K

Put Options Held

141K

View Full List

About Amneal Pharmaceuticals, Inc.

Ticker AMRX
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 151,408,992
Market Cap $1.19B
Description
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and comme...

More about AMRX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account